116 related articles for article (PubMed ID: 16197815)
21. Safety and efficacy of first-in-man intrathecal injection of human astrocytes (AstroRx®) in ALS patients: phase I/IIa clinical trial results.
Gotkine M; Caraco Y; Lerner Y; Blotnick S; Wanounou M; Slutsky SG; Chebath J; Kuperstein G; Estrin E; Ben-Hur T; Hasson A; Molakandov K; Sonnenfeld T; Stark Y; Revel A; Revel M; Izrael M
J Transl Med; 2023 Feb; 21(1):122. PubMed ID: 36788520
[TBL] [Abstract][Full Text] [Related]
22. Free insulin-like growth factor (IGF)-I and IGF binding proteins 2, 5, and 6 in spinal motor neurons in amyotrophic lateral sclerosis.
Wilczak N; de Vos RA; De Keyser J
Lancet; 2003 Mar; 361(9362):1007-11. PubMed ID: 12660059
[TBL] [Abstract][Full Text] [Related]
23. Riluzole and amyotrophic lateral sclerosis survival: a population-based study in southern Italy.
Zoccolella S; Beghi E; Palagano G; Fraddosio A; Guerra V; Samarelli V; Lepore V; Simone IL; Lamberti P; Serlenga L; Logroscino G;
Eur J Neurol; 2007 Mar; 14(3):262-8. PubMed ID: 17355545
[TBL] [Abstract][Full Text] [Related]
24. A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group.
Borasio GD; Robberecht W; Leigh PN; Emile J; Guiloff RJ; Jerusalem F; Silani V; Vos PE; Wokke JH; Dobbins T
Neurology; 1998 Aug; 51(2):583-6. PubMed ID: 9710040
[TBL] [Abstract][Full Text] [Related]
25. Comparison of the growth hormone, IGF-1 and insulin in cerebrospinal fluid and serum between patients with motor neuron disease and healthy controls.
Bilic E; Bilic E; Rudan I; Kusec V; Zurak N; Delimar D; Zagar M
Eur J Neurol; 2006 Dec; 13(12):1340-5. PubMed ID: 17116217
[TBL] [Abstract][Full Text] [Related]
26. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial.
Sorenson EJ; Windbank AJ; Mandrekar JN; Bamlet WR; Appel SH; Armon C; Barkhaus PE; Bosch P; Boylan K; David WS; Feldman E; Glass J; Gutmann L; Katz J; King W; Luciano CA; McCluskey LF; Nash S; Newman DS; Pascuzzi RM; Pioro E; Sams LJ; Scelsa S; Simpson EP; Subramony SH; Tiryaki E; Thornton CA
Neurology; 2008 Nov; 71(22):1770-5. PubMed ID: 19029516
[TBL] [Abstract][Full Text] [Related]
27. Insulin-like growth factor-I for the treatment of amyotrophic lateral sclerosis.
Sakowski SA; Schuyler AD; Feldman EL
Amyotroph Lateral Scler; 2009 Apr; 10(2):63-73. PubMed ID: 18608100
[TBL] [Abstract][Full Text] [Related]
28. Mecasermin (recombinant human insulin-like growth factor I).
Rosenbloom AL
Adv Ther; 2009 Jan; 26(1):40-54. PubMed ID: 19198769
[TBL] [Abstract][Full Text] [Related]
29. Intravenous thyrotropin releasing hormone in amyotrophic lateral sclerosis: autonomic effects.
Beaulieu DA; Erickson L; Williams A; Sufit RL; Brooks BR
Neurol Clin; 1987 May; 5(2):269-90, vi. PubMed ID: 11681403
[TBL] [Abstract][Full Text] [Related]
30. Developments in treatments for amyotrophic lateral sclerosis via intracerebroventricular or intrathecal delivery.
Van Damme P; Robberecht W
Expert Opin Investig Drugs; 2014 Jul; 23(7):955-63. PubMed ID: 24816247
[TBL] [Abstract][Full Text] [Related]
31. Increased expression of insulin-like growth factor I in skin in amyotrophic lateral sclerosis.
Ono S; Hu J; Imai T; Shimizu N; Tsumura M; Nakagawa H
J Neurol Neurosurg Psychiatry; 2000 Aug; 69(2):199-203. PubMed ID: 10896693
[TBL] [Abstract][Full Text] [Related]
32. Effects of recombinant human insulin-like growth factor I (IGF-I) therapy on the growth hormone-IGF system of a patient with a partial IGF-I gene deletion.
Camacho-Hübner C; Woods KA; Miraki-Moud F; Hindmarsh PC; Clark AJ; Hansson Y; Johnston A; Baxter RC; Savage MO
J Clin Endocrinol Metab; 1999 May; 84(5):1611-6. PubMed ID: 10323388
[TBL] [Abstract][Full Text] [Related]
33. The immunomodulatory effects of human mesenchymal stem cells on peripheral blood mononuclear cells in ALS patients.
Kwon MS; Noh MY; Oh KW; Cho KA; Kang BY; Kim KS; Kim YS; Kim SH
J Neurochem; 2014 Oct; 131(2):206-18. PubMed ID: 24995608
[TBL] [Abstract][Full Text] [Related]
34. Intrathecal transplantation of human neural stem cells overexpressing VEGF provide behavioral improvement, disease onset delay and survival extension in transgenic ALS mice.
Hwang DH; Lee HJ; Park IH; Seok JI; Kim BG; Joo IS; Kim SU
Gene Ther; 2009 Oct; 16(10):1234-44. PubMed ID: 19626053
[TBL] [Abstract][Full Text] [Related]
35. Rapid progression of amyotrophic lateral sclerosis in an acromegalic patient after surgical resection of a growth hormone-producing pituitary adenoma.
Mondok A; Aranyi Z; Kovacs GG; Czirjak S; Pusztai P; Varga I; Racz K
Neurologist; 2010 Sep; 16(5):315-8. PubMed ID: 20827122
[TBL] [Abstract][Full Text] [Related]
36. Intraspinal cord delivery of IGF-I mediated by adeno-associated virus 2 is neuroprotective in a rat model of familial ALS.
Franz CK; Federici T; Yang J; Backus C; Oh SS; Teng Q; Carlton E; Bishop KM; Gasmi M; Bartus RT; Feldman EL; Boulis NM
Neurobiol Dis; 2009 Mar; 33(3):473-81. PubMed ID: 19135533
[TBL] [Abstract][Full Text] [Related]
37. [Restorative therapy in amyotrophic lateral sclerosis].
Aoki M
Nihon Shinkei Seishin Yakurigaku Zasshi; 2012 Nov; 32(5-6):287-92. PubMed ID: 23373317
[TBL] [Abstract][Full Text] [Related]
38. Natural history of amyotrophic lateral sclerosis. Observations with the Charing Cross Amyotrophic Lateral Sclerosis Rating Scales.
Guiloff RJ; Goonetilleke A
Adv Neurol; 1995; 68():185-98. PubMed ID: 8787229
[TBL] [Abstract][Full Text] [Related]
39. Trial of celecoxib in amyotrophic lateral sclerosis.
Cudkowicz ME; Shefner JM; Schoenfeld DA; Zhang H; Andreasson KI; Rothstein JD; Drachman DB
Ann Neurol; 2006 Jul; 60(1):22-31. PubMed ID: 16802291
[TBL] [Abstract][Full Text] [Related]
40. The pathogenesis of ALS: implications for treatment strategies.
Silani V; Braga M; Cardin V; Scarlato G
Neurol Neurochir Pol; 2001; 35(1 Suppl):25-39. PubMed ID: 11732278
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
